{"id":19301,"date":"2021-12-14T11:54:06","date_gmt":"2021-12-14T10:54:06","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=19301"},"modified":"2021-12-14T11:54:10","modified_gmt":"2021-12-14T10:54:10","slug":"cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/","title":{"rendered":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases"},"content":{"rendered":"\n

Published on the Center for Diseases Control and Prevention website<\/a>, updateUpdated December 7, 2021<\/p>\n\n\n\n

The Centers for Disease Control and Prevention (CDC) announced today that it has awarded $22 million to nearly 30 organizations around the world to combat antimicrobial resistance (AR) and other healthcare threats through the establishment of two new networks\u2014the Global Action in Healthcare Network (GAIHN) and the Global AR Laboratory and Response Network (Global AR Lab & Response Network).<\/p>\n\n\n\n

These two new networks, paired with additional short-term research projects, will span more than 50 countries worldwide and build programs that focus on preventing infections in health care through proven infection control; build laboratory capacity to detect antimicrobial-resistant organisms in healthcare, the community, and environment; and develop new and innovative ways to more rapidly detect and respond to threats like AR and COVID-19.<\/p>\n\n\n\n

This work builds on successful U.S. efforts launched through CDC\u2019s AR Solutions Initiative since 2016 and will complement ongoing, effective global work underway by CDC and public health partners worldwide. These networks and research projects will tackle threats covered in\u00a0CDC\u2019s\u00a0Antibiotic Resistance Threats in the United States, 2019<\/em><\/a>\u00a0and other healthcare-associated infections.<\/p>\n\n\n\n

\u201cAntimicrobial resistance is not going away and new AR threats will continue to emerge. CDC\u2019s domestic AR Lab Network is an established model for detecting emerging antimicrobial resistance threats. Today, these new investments will build on this model and span much of the globe, leveraging proven expertise to fill critical gaps and inform data-driven responses before threats can spread in communities, across borders, or around the world,\u201d said Denise Cardo, MD, Director of CDC\u2019s Division of Healthcare Quality Promotion. \u201cWe also know that evidence-based prevention in health care stops AR threats and other infectious diseases. These new programs will fill infection control gaps to keep patients safe and contain threats immediately when they do inevitably emerge.\u201d<\/p>\n\n\n\n

The 28 organizations receiving funding include: American Society for Microbiology (ASM); American Type Culture Collection (ATCC); American University of Beirut; Association of Public Health Laboratories (APHL); Columbia University; Duke University; Family Health International (FHI360); FIOTEC; Global Scientific Solutions for Health; Health Security Partners; icddr,b; Johns Hopkins University; Koperasi Jasa Institut Riset Eijkman; Northwestern University; Pakistan National Institute of Health; Pan American Health Organization (PAHO); The Ohio State University; U.S. Civilian Research & Development Foundation (CRDF); Universidad de Desarrollo; University of Campinas; University of Cantabria; University of Nairobi; University of Oxford; University of Pennsylvania; Vanderbilt University; Washington State University; Washington University  in St. Louis; and World Health Organization (WHO).<\/p>\n\n\n\n

These institutions received these awards through a competitive selection process based on scientific needs and funds available.<\/p>\n\n\n\n

In addition to these networks, CDC has also invested in short-term global AR innovation research projects, working with investigators to identify new public health solutions to prevent antimicrobial-resistant infections and their spread. Findings from the global AR innovation projects may later be integrated into the Global AR Lab & Response Network to transform the way the world responds to AR across the\u00a0One Health<\/a>\u00a0spectrum.<\/p>\n\n\n\n

Read more about the first global AR innovation projects.<\/a><\/p>\n\n\n\n

CDC\u2019s vision for the Global Action in Healthcare Network (GAIHN) is to create a global collaborative network of countries, institutions, and partners at global, regional, national, and subnational levels that will address and reduce priority emerging infections in healthcare settings. GAIHN will do so through detection and response, including infection prevention and control. Health care can often be an epicenter of infectious disease outbreaks that can spread within and beyond the facility into the community. Partners will reduce healthcare-associated infections, deliver safer health care, ensure that facilities and countries are better prepared to respond to emerging threats in health care, and control and prevent outbreaks and emergencies\u2014such as AR and COVID-19\u2014in healthcare facilities and affected communities including AR and COVID-19.\u00a0See the list organizations participating in GAIHN\u2019s first year.<\/a><\/p>\n\n\n\n

CDC\u2019s Global AR Lab & Response Network will improve the detection of emerging AR threats and identify risk factors that drive the emergence and spread of AR across health care, the community, and the environment (the One Health spectrum). This new network will build on successes of its sister program, the U.S. AR Lab Network, which was established in 2016. It will target emerging and existing AR threats, such as healthcare pathogens, drug-resistant enteric pathogens, fungal pathogens, invasive bacterial and respiratory pathogens, and Neisseria gonorrhoeae. The Global AR Lab & Response Network will also collaborate with GAIHN in growing laboratory expertise and detecting AR threats in health care. See the awardees and read more about the Global AR Lab & Response Network\u2019s first-year collaborations.\u00a0<\/p>\n\n\n\n

See the awardees and read more about the Global AR Lab & Response Network\u2019s first-year collaborations.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Published on the Center for Diseases Control and Prevention website, updateUpdated December 7, 2021 The Centers for Disease Control and Prevention (CDC) announced today that it has awarded $22 million to nearly 30 organizations around the world to combat antimicrobial resistance (AR) and other healthcare threats through the establishment of two new networks\u2014the Global Action […]<\/p>\n","protected":false},"author":139,"featured_media":19305,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[58],"tags":[],"acf":[],"yoast_head":"\nCDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2021-12-14T10:54:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-12-14T10:54:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"491\" \/>\n\t<meta property=\"og:image:height\" content=\"476\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases\",\"datePublished\":\"2021-12-14T10:54:06+00:00\",\"dateModified\":\"2021-12-14T10:54:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\"},\"wordCount\":797,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\",\"name\":\"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg\",\"datePublished\":\"2021-12-14T10:54:06+00:00\",\"dateModified\":\"2021-12-14T10:54:10+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg\",\"width\":491,\"height\":476,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/","og_locale":"en_GB","og_type":"article","og_title":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2021-12-14T10:54:06+00:00","article_modified_time":"2021-12-14T10:54:10+00:00","og_image":[{"width":491,"height":476,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases","datePublished":"2021-12-14T10:54:06+00:00","dateModified":"2021-12-14T10:54:10+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/"},"wordCount":797,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg","articleSection":["News"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/","name":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg","datePublished":"2021-12-14T10:54:06+00:00","dateModified":"2021-12-14T10:54:10+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/12\/Dollars.jpg","width":491,"height":476,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/cdc-launches-two-global-networks-awards-22-million-to-combat-antimicrobial-resistance-and-infectious-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"CDC Launches Two Global Networks, Awards $22 Million to Combat Antimicrobial Resistance and Infectious Diseases"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-12 16:37:40","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19301"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=19301"}],"version-history":[{"count":1,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19301\/revisions"}],"predecessor-version":[{"id":19303,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/19301\/revisions\/19303"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/19305"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=19301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=19301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=19301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}